Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Dissolving scaffold could open blocked leg arteries without permanent implants

NCT ID NCT07290101

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new device that opens blocked arteries in the pelvis and leg. The scaffold is made of a material that dissolves over time, so nothing stays in the body permanently. The trial will include 15 people with pain while walking or at rest due to narrowed or blocked iliac arteries. Doctors will check if the device is safe and works well at keeping the artery open.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: General inclusion criteria 1. Patients with stenosis or occlusion of the common iliac artery and/or external iliac artery caused by atherosclerosis. 2. Age between 18 - 85 years old. Male or non-pregnant female. 3. Patients with intermittent claudication (Rutherford category 2-3) or ischemic rest pain (Rutherford category 4). 4. Patients who can understand the purpose of the trial, voluntarily participate and sign the informed consent form, and are willing to complete the follow-up according to the protocol requirements. Angiographic Inclusion Criteria 1. Patients with evidence of unilateral or bilateral de novo or restenosis (non-stent treatment) lesion(s) in the common iliac artery and/or external iliac artery, with the stenosis degree of the target lesion being≥50% (including occlusion). 2. The target lesion(s) can be successfully crossed with a guide wire and pre-dilated with an appropriately sized balloon. 3. The target lesion(s) with reference vessel diameter between 4.0 mm and 12.0 mm, and total length of unilateral lesion(s) ≤ 100 mm (tandem lesions are allowed). 4. Up to two ipsilateral target lesions or bilateral lesions are allowed (one target lesion per limb, with the length adhering to the unilateral criterion). Up to two stents are allowed for stent overlap per side (i.e., a maximum of two stents can be implanted per side). 5. Patients with angiographic evidence of patent outflow vessels in the target limb, including: a healthy common femoral artery (\<50% stenosis); at least one of the deep femoral artery or superficial femoral artery is patent (\<50% stenosis); a healthy popliteal artery (\<50% stenosis); and at least one patent infrapopliteal vessel connected (\<50% stenosis). 6. For stenotic or occlusive target lesion(s) located at the ostium of the common iliac artery without a residual stump, intervention can be achieved through kissing stent technique. Exclusion Criteria: General exclusion criteria 1. Patients with previously stented target lesion. 2. Patients who have undergone lower extremity arterial intervention within 30 days before the index procedure, or has such intervention planned for within 30 days after the index procedure. 3. Patients with a history of or planned ipsilateral aortoiliac bypass surgery during the index procedure. 4. Patients who were expected to undergo amputation of the target limb before the index procedure. 5. Patients with an aneurysm, perforation and/or dissection of the target iliac artery before the index procedure. 6. Patients who have undergone coronary artery intervention within 30 days before the index procedure, or has such intervention planned for within 30 days after the index procedure (including the index procedure). 7. Patients with acute myocardial infarction or angina pectoris within 30 days before the index procedure. 8. Patients with a stroke within 3 months before the index procedure, or a stroke more than 3 months before the index procedure accompanied by severe paralysis and aphasia sequelae. 9. Patients with known intolerance to antiplatelet, anticoagulant, or thrombolytic medications. 10. Patients with known diseases (not related to the trial) that require indefinite or lifelong anticoagulation therapy. 11. Patients with known allergies to aspirin, heparin, clopidogrel, contrast agent, poly(lactide), iron and its degradation products. 12. Patients with a history of iron overload or iron disorder, such as hereditary hemochromatosis, etc. 13. Patients with coagulation insufficiency (platelet count \< 80\*109/L), systemic coagulation disorders or hypercoagulable tendencies. 14. Patients with severe hepatic or renal insufficiency (serum creatinine \>2 times the upper limit of normal or on renal dialysis; ALT or AST \> 5 times the upper limit of normal). 15. Patients with a life expectancy of less than two years. 16. Patient currently participating in another clinical trial, and have not yet completed that trial. 17. Patients who are not suitable for participating the trial as per investigator judgement. Angiographic Exclusion Criteria 1. Patients with angiographic evidence of thrombus within or adjacent to the target lesion(s). 2. Patients with a history of ipsilateral iliac artery stenting, where the distance between the previously implanted stent and the current target lesion is ≤ 5 mm. 3. Patients with coexisting ipsilateral iliac aneurysms or abdominal aortic aneurysms. 4. Patients in whom the internal iliac artery is patent, but implanting the stent in the target lesion will block the blood flow from entering the internal iliac artery. 5. Patients requiring placement of a study device within 2 cm proximal to the inguinal ligament. 6. Patients with severe calcification of the target lesion which makes it impossible for the pre-dilation balloon to reach its nominal diameter.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Iliac artery occlusion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.